|
|
1p缺失在多发性骨髓瘤中的研究进展
|
Abstract:
多发性骨髓瘤(MM)是终末分化的B细胞恶性肿瘤，被广泛认为是无法治愈的，因为许多患者要么产生了耐药性，要么最终复发。为了制定精确有效的治疗策略，我们必须了解MM的发病机制。在本综述中，我们描述了一些肿瘤抑制因子在1p缺失中丢失或下调，总结了它们的生物学功能及其在MM发病机制中的作用，希望发现潜在的治疗靶点，促进未来治疗方法的发展。
Multiple myeloma (MM) is a terminally differentiated B-cell malignancy that is widely considered incurable because many patients either develop drug resistance or eventually relapse. In order to develop accurate and effective treatment strategies, we must understand the pathogenesis of MM. In this review, we describe the loss or down-regulation of some tumor suppressors in 1p deletion, summarize their biological functions and their roles in the pathogenesis of MM, and hope to find potential therapeutic targets and promote the development of future treatment methods.
| [1] | 中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订) [J]. 中华内科杂志, 2022, 61(5): 480-487. |
| [2] | Rajkumar, S.V. (2022) Multiple Myeloma: 2022 Update on Diagnosis, Risk Strati-fication, and Management. American Journal of Hematology, 97, 1086-1107. https://doi.org/10.1002/ajh.26590 |
| [3] | Silberstein, J., Tuchman, S. and Grant, S.J. (2022) What Is Multiple Mye-loma? JAMA, 327, 497.
https://doi.org/10.1001/jama.2021.25306 |
| [4] | Boise, L.H., Kaufman, J.L., Bahlis, N.J., et al. (2014) The Tao of Myeloma. Blood, 124, 1873-1879.
https://doi.org/10.1182/blood-2014-05-578732 |
| [5] | Luo, S., Su, T., Zhou, X., et al. (2022) Chromosome 1 Insta-bility in Multiple Myeloma: Aberrant Gene Expression, Pathogenesis, and Potential Therapeutic Target. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 36, e22341. https://doi.org/10.1096/fj.202200354 |
| [6] | Neuse, C.J., Lomas, O.C., Schliemann, C., et al. (2020) Genome Insta-bility in Multiple Myeloma. Leukemia, 34, 2887-2897.
https://doi.org/10.1038/s41375-020-0921-y |
| [7] | Hultcrantz, M., Yellapantula, V. and Rustad, E.H. (2020) Ge-nomic Profiling of Multiple Myeloma: New Insights and Modern Technologies. Best Practice & Research Clinical Haematology, 33, Article ID: 101153.
https://doi.org/10.1016/j.beha.2020.101153 |
| [8] | Giri, S., Huntington, S.F., Wang, R., et al. (2020) Chromosome 1 Abnormalities and Survival of Patients with Multiple Myeloma in the Era of Novel Agents. Blood Advances, 4, 2245-2253.
https://doi.org/10.1182/bloodadvances.2019001425 |
| [9] | Panani, A.D., Ferti, A.D., Papaxoinis, C., et al. (2004) Cytogenetic Data as a Prognostic Factor in Multiple Myeloma Patients: Involvement of 1p12 Region an Adverse Prog-nostic Factor. Anticancer Research, 24, 4141-4146. |
| [10] | Boyd, K.D., Ross, F.M., Walker, B.A., et al. (2011) Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Re-gions Associated with Adverse Survival. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 7776-7784.
https://doi.org/10.1158/1078-0432.CCR-11-1791 |
| [11] | Lohr, J.G., Stojanov, P., Carter, S.L., et al. (2014) Wide-spread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 25, 91-101. https://doi.org/10.1016/j.ccr.2013.12.015 |
| [12] | Liu, S., Chen, H., Yin, Y., et al. (2023) Inhibition of FAM46/TENT5 Activity by BCCIPα Adopting a Unique Fold. Science Advances, 9, eadf5583. https://doi.org/10.1126/sciadv.adf5583 |
| [13] | Zhang, H., Zhang, S.-H., Hu, J.-L., et al. (2021) Structural and Func-tional Characterization of Multiple Myeloma Associated Cytoplasmic poly(A) Polymerase FAM46C. Cancer Communi-cations (London, England), 41, 615-630.
https://doi.org/10.1002/cac2.12163 |
| [14] | Manfrini, N., Mancino, M., Miluzio, A., et al. (2020) FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy. Cancer Research, 80, 4693-4706.
https://doi.org/10.1158/0008-5472.CAN-20-1357 |
| [15] | Kanasugi, J., Hanamura, I., Ota, A., et al. (2020) Biallelic Loss of FAM46C Triggers Tumor Growth with Concomitant Activation of Akt Signaling in Multiple Myeloma Cells. Cancer Science, 111, 1663-1675.
https://doi.org/10.1111/cas.14386 |
| [16] | Comet, I., Riising, E.M., Leblanc, B., et al. (2016) Maintaining Cell Identity: PRC2-Mediated Regulation of Transcription and Cancer. Nature Reviews. Cancer, 16, 803-810. https://doi.org/10.1038/nrc.2016.83 |
| [17] | Perino, M., van Mierlo, G., Karemaker, I.D., et al. (2018) MTF2 Recruits Polycomb Repressive Complex 2 by Helical-Shape-Selective DNA Binding. Nature Genetics, 50, 1002-1010. https://doi.org/10.1038/s41588-018-0134-8 |
| [18] | Saul, M.C., Majdak, P., Perez, S., et al. (2017) High Motivation for Exercise Is Associated with Altered Chromatin Regulators of Monoamine Receptor Gene Expression in the Striatum of Selectively Bred Mice. Genes, Brain, and Behavior, 16, 328-341. https://doi.org/10.1111/gbb.12347 |
| [19] | Yang, Z., Sun, Q., Guo, J., et al. (2019) GRSF1-Mediated MIR-G-1 Promotes Malignant Behavior and Nuclear Autophagy by Directly Upregulating TMED5 and LMNB1 in Cervical Cancer Cells. Autophagy, 15, 668-685.
https://doi.org/10.1080/15548627.2018.1539590 |
| [20] | Liu, Y., Yu, H., Yoo, S., et al. (2019) A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers, 11, 1452. https://doi.org/10.3390/cancers11101452 |
| [21] | Yan, M., Niu, L., Liu, J., et al. (2021) circEVI5 Acts as a miR-4793-3p Sponge to Suppress the Proliferation of Gastric Cancer. Cell Death & Disease, 12, 774. https://doi.org/10.1038/s41419-021-04061-4 |
| [22] | Ma？ecki, J.M., Odonohue, M.-F., Kim, Y., et al. (2021) Human METTL18 Is a Histidine-Specific Methyltransferase That Targets RPL3 and Affects Ribosome Biogenesis and Function. Nucleic Acids Research, 49, 3185-3203.
https://doi.org/10.1093/nar/gkab088 |
| [23] | ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2023) Author Correction: Pan-Cancer Analysis of Whole Genomes. Nature, 614, E39. |
| [24] | Hofman, I.J.F., Patchett, S., van Duin, M., et al. (2017) Low Frequency Mutations in Ribosomal Proteins RPL10 and RPL5 in Multiple Myeloma. Haematologica, 102, e317-e320. https://doi.org/10.3324/haematol.2016.162198 |
| [25] | Hofman, I.J.F., van Duin, M., Bruyne, E., et al. (2017) RPL5 on 1p22.1 Is Recurrently Deleted in Multiple Myeloma and Its Expression Is Linked to Bortezomib Response. Leukemia, 31, 1706-1714. https://doi.org/10.1038/leu.2016.370 |
| [26] | Zhang, A., Huang, Z., Tao, W., et al. (2022) USP33 Deubiquitinates and Stabilizes HIF-2alpha to Promote Hypoxia Response in Glioma Stem Cells. The EMBO Journal, 41, e109187. https://doi.org/10.15252/embj.2021109187 |
| [27] | Kitamura, H. (2023) Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders. International Journal of Molecular Sciences, 24, 3219. https://doi.org/10.3390/ijms24043219 |
| [28] | Chen, S., Liang, Y., Shen, Y., et al. (2023) lncRNA XIST/miR-129-2-3p Axis Targets CCP110 to Regulate the Proliferation, Invasion and Migration of Endometrial Cancer Cells. Experimental and Therapeutic Medicine, 25, Article No. 159. https://doi.org/10.3892/etm.2023.11858 |
| [29] | Simicek, M., Lievens, S., Laga, M., et al. (2013) The Deubiquitylase USP33 Discriminates between RALB Functions in Autophagy and Innate Immune Response. Nature Cell Biology, 15, 1220-1230. https://doi.org/10.1038/ncb2847 |
| [30] | Chng, W.J., Gertz, M.A., Chung, T.-H., et al. (2010) Correlation between Array-Comparative Genomic Hybridization-Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 Deletion as a Prognostic Factor in Myeloma. Leukemia, 24, 833-842. https://doi.org/10.1038/leu.2010.21 |
| [31] | Clark, N., Wu, X. and Her, C. (2013) MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases. Current Genomics, 14, 81-90. https://doi.org/10.2174/1389202911314020002 |
| [32] | Li, L., Hao, J., Yan, C.-Q., et al. (2020) Inhibition of mi-croRNA-300 Inhibits Cell Adhesion, Migration, and Invasion of Prostate Cancer Cells by Promoting the Expression of DAB1. Cell Cycle (Georgetown, Tex.), 19, 2793-2810.
https://doi.org/10.1080/15384101.2020.1823730 |
| [33] | Wang, H., Meng, H., Wang, J., et al. (2020) Clinical Char-acteristics and Prognostic Values of 1p32.3 Deletion Detected through Fluorescence in Situ Hybridization in Patients with Newly Diagnosed Multiple Myeloma: A Single-Center Study in China. Frontiers of Medicine, 14, 327-334. https://doi.org/10.1007/s11684-019-0712-x |
| [34] | Hebraud, B., Leleu, X., Lauwers-Cances, V., et al. (2014) Dele-tion of the 1p32 Region Is a Major Independent Prognostic Factor in Young Patients with Myeloma: The IFM Experi-ence on 1195 Patients. Leukemia, 28, 675-679.
https://doi.org/10.1038/leu.2013.225 |
| [35] | Bretz, J., Garcia, J., Huang, X., et al. (2011) Noxa Mediates p18INK4c Cell-Cycle Control of Homeostasis in B Cells and Plasma Cell Precursors. Blood, 117, 2179-2188. https://doi.org/10.1182/blood-2010-06-288027 |
| [36] | Morse, L., Chen, D., Franklin, D., et al. (1997) Induction of Cell Cycle Arrest and B Cell Terminal Differentiation by CDK Inhibitor p18(INK4c) and IL-6. Immunity, 6, 47-56. https://doi.org/10.1016/S1074-7613(00)80241-1 |
| [37] | Kulkarni, M.S., Daggett, J.L., Bender, T.P., et al. (2002) Frequent Inactivation of the Cyclin-Dependent Kinase Inhibitor p18 by Homozygous Deletion in Multiple Myeloma Cell Lines: Ectopic p18 Expression Inhibits Growth and Induces Apoptosis. Leukemia, 16, 127-134. https://doi.org/10.1038/sj.leu.2402328 |
| [38] | Adamia, S., Bhatt, S., Wen, K., et al. (2022) Combination Therapy Targeting Erk1/2 and CDK4/6i in Relapsed Refractory Multiple Myeloma. Leukemia, 36, 1088-1101. https://doi.org/10.1038/s41375-021-01475-z |
| [39] | Franz, A., Pirson, P.A., Pilger, D., et al. (2016) Chroma-tin-Associated Degradation Is Defined by UBXN-3/FAF1 to Safeguard DNA Replication Fork Progression. Nature Communications, 7, Article No. 10612.
https://doi.org/10.1038/ncomms10612 |
| [40] | Li, Y., Wu, X., Li, J., et al. (2022) Circ_0004354 Might Compete with Circ_0040039 to Induce NPCs Death and Inflammatory Response by Targeting miR-345-3p-FAF1/TP73 Axis in Inter-vertebral Disc Degeneration. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 2776440. https://doi.org/10.1155/2022/2776440 |
| [41] | Song, S., Park, J.K., Shin, S.C., et al. (2022) The Complex of Fas-Associated Factor 1 with Hsp70 Stabilizes the Adherens Junction Integrity by Suppressing RhoA Activation. Jour-nal of Molecular Cell Biology, 14, mjac037.
https://doi.org/10.1093/jmcb/mjac037 |
| [42] | Xie, F., Jin, K., Shao, L., et al. (2017) FAF1 Phosphorylation by AKT Accumulates TGF-β Type II Receptor and Drives Breast Cancer Metastasis. Nature Communications, 8, Article No. 15021.
https://doi.org/10.1038/ncomms15021 |
| [43] | Omran, Z., Dalhat, M., Abdullah, O., et al. (2021) Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors. Cancers, 13, 1916. https://doi.org/10.3390/cancers13081916 |
| [44] | Schultheis, B., Kr？mer, A., Willer, A., et al. (1999) Analysis of p73 and p53 Gene Deletions in Multiple Myeloma. Leukemia, 13, 2099-2103. https://pubmed.ncbi.nlm.nih.gov/10602435 https://doi.org/10.1038/sj.leu.2401609 |
| [45] | Saha, M.N., Jiang, H., Yang, Y., Reece, D. and Chang, H. (2018) Correction: PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma by Induction of p73 and Noxa. Molecular Cancer Therapeutics, 17, 1143.
https://pubmed.ncbi.nlm.nih.gov/29717080 https://doi.org/10.1158/1535-7163.MCT-18-0096 |
